EdgeRock Capital LLC Acquires New Stake in Eli Lilly and Company $LLY

Key Points

• EdgeRock Capital LLC acquired a new stake in Eli Lilly and Company by purchasing 917 shares valued at approximately $714,000.
• Multiple institutional investors, including American National Bank & Trust and BankPlus Wealth Management, increased their holdings in Eli Lilly during the 2nd quarter.
• Eli Lilly reported a quarterly EPS of $6.31, surpassing analyst estimates, and set its FY 2025 guidance at 21.750-23.000 EPS.

EdgeRock Capital LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 917 shares of the company's stock, valued at approximately $714,000.

Several other large investors also recently added to or reduced their stakes in the stock. Patron Partners LLC grew its holdings in Eli Lilly and Company by 6.7% in the 2nd quarter. Patron Partners LLC now owns 3,968 shares of the company's stock valued at $3,093,000 after buying an additional 250 shares in the last quarter. BankPlus Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. BankPlus Wealth Management LLC now owns 1,006 shares of the company's stock worth $784,000 after purchasing an additional 25 shares during the period. CX Institutional grew its holdings in shares of Eli Lilly and Company by 5.5% during the 2nd quarter. CX Institutional now owns 28,717 shares of the company's stock worth $22,385,000 after purchasing an additional 1,494 shares during the period. American National Bank & Trust grew its holdings in shares of Eli Lilly and Company by 23.8% during the 2nd quarter. American National Bank & Trust now owns 17,515 shares of the company's stock worth $13,653,000 after purchasing an additional 3,368 shares during the period. Finally, Bank Pictet & Cie Europe AG lifted its stake in Eli Lilly and Company by 3.9% during the 2nd quarter. Bank Pictet & Cie Europe AG now owns 69,529 shares of the company's stock worth $54,200,000 after acquiring an additional 2,597 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $724.73 on Friday. The stock has a market cap of $685.93 billion, a price-to-earnings ratio of 47.37, a price-to-earnings-growth ratio of 0.99 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The business has a fifty day moving average of $734.15 and a 200-day moving average of $767.20.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the business earned $3.92 earnings per share. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LLY shares. Cantor Fitzgerald reduced their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Finally, Leerink Partners restated a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.